Neoadjuvant chemotherapy use in bladder cancer: A survey of current practice and opinions

N. G. Cowan, Yiyi Chen, T. M. Downs, B. H. Bochner, A. B. Apolo, M. P. Porter, J. C. La Rochelle, Christopher Amling, Theresa Koppie

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Objectives. Level 1 evidence supports the use of neoadjuvant chemotherapy (NAC) to improve overall survival in muscle invasive bladder cancer; however utilization rates remain low. The aims of our study were to determine factors associated with NAC use, to more clearly define reasons for low utilization, and to determine the current rate of NAC use among urologic oncologists. Materials and Methods. Active members of the Society for Urologic Oncology were provided a 20-question survey. Descriptive statistical analysis was conducted for each question and univariate analysis was performed. Results. We achieved a response rate of 21%. Clinical T3/T4 disease was the most often selected reason for recommending NAC (87%). Concerns with recommending NAC were age and comorbidities (54%) followed by delay in surgery (35%). An association was identified between urologic oncologists who discussed NAC with >90% of their patients and medical oncologists "always" recommending NAC (P=0.0009). NAC utilization rate was between 30 and 57%. Conclusions. Amongst this highly specialized group of respondents, clinical T3-T4 disease was the most common reason for implementation of NAC. Respondents who frequently discussed NAC were more likely to report their medical oncologist always recommending NAC. Reported NAC use was higher in this surveyed group (30-57%) compared with recently published rates.

Original languageEnglish (US)
Article number746298
JournalAdvances in Urology
DOIs
StatePublished - 2014

Fingerprint

Urinary Bladder Neoplasms
Drug Therapy
Surveys and Questionnaires
Comorbidity
Muscles
Survival

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Urology

Cite this

Cowan, N. G., Chen, Y., Downs, T. M., Bochner, B. H., Apolo, A. B., Porter, M. P., ... Koppie, T. (2014). Neoadjuvant chemotherapy use in bladder cancer: A survey of current practice and opinions. Advances in Urology, [746298]. https://doi.org/10.1155/2014/746298

Neoadjuvant chemotherapy use in bladder cancer : A survey of current practice and opinions. / Cowan, N. G.; Chen, Yiyi; Downs, T. M.; Bochner, B. H.; Apolo, A. B.; Porter, M. P.; La Rochelle, J. C.; Amling, Christopher; Koppie, Theresa.

In: Advances in Urology, 2014.

Research output: Contribution to journalArticle

Cowan, N. G. ; Chen, Yiyi ; Downs, T. M. ; Bochner, B. H. ; Apolo, A. B. ; Porter, M. P. ; La Rochelle, J. C. ; Amling, Christopher ; Koppie, Theresa. / Neoadjuvant chemotherapy use in bladder cancer : A survey of current practice and opinions. In: Advances in Urology. 2014.
@article{8d2e63549a154eafad77654acc73e0f4,
title = "Neoadjuvant chemotherapy use in bladder cancer: A survey of current practice and opinions",
abstract = "Objectives. Level 1 evidence supports the use of neoadjuvant chemotherapy (NAC) to improve overall survival in muscle invasive bladder cancer; however utilization rates remain low. The aims of our study were to determine factors associated with NAC use, to more clearly define reasons for low utilization, and to determine the current rate of NAC use among urologic oncologists. Materials and Methods. Active members of the Society for Urologic Oncology were provided a 20-question survey. Descriptive statistical analysis was conducted for each question and univariate analysis was performed. Results. We achieved a response rate of 21{\%}. Clinical T3/T4 disease was the most often selected reason for recommending NAC (87{\%}). Concerns with recommending NAC were age and comorbidities (54{\%}) followed by delay in surgery (35{\%}). An association was identified between urologic oncologists who discussed NAC with >90{\%} of their patients and medical oncologists {"}always{"} recommending NAC (P=0.0009). NAC utilization rate was between 30 and 57{\%}. Conclusions. Amongst this highly specialized group of respondents, clinical T3-T4 disease was the most common reason for implementation of NAC. Respondents who frequently discussed NAC were more likely to report their medical oncologist always recommending NAC. Reported NAC use was higher in this surveyed group (30-57{\%}) compared with recently published rates.",
author = "Cowan, {N. G.} and Yiyi Chen and Downs, {T. M.} and Bochner, {B. H.} and Apolo, {A. B.} and Porter, {M. P.} and {La Rochelle}, {J. C.} and Christopher Amling and Theresa Koppie",
year = "2014",
doi = "10.1155/2014/746298",
language = "English (US)",
journal = "Advances in Urology",
issn = "1687-6369",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - Neoadjuvant chemotherapy use in bladder cancer

T2 - A survey of current practice and opinions

AU - Cowan, N. G.

AU - Chen, Yiyi

AU - Downs, T. M.

AU - Bochner, B. H.

AU - Apolo, A. B.

AU - Porter, M. P.

AU - La Rochelle, J. C.

AU - Amling, Christopher

AU - Koppie, Theresa

PY - 2014

Y1 - 2014

N2 - Objectives. Level 1 evidence supports the use of neoadjuvant chemotherapy (NAC) to improve overall survival in muscle invasive bladder cancer; however utilization rates remain low. The aims of our study were to determine factors associated with NAC use, to more clearly define reasons for low utilization, and to determine the current rate of NAC use among urologic oncologists. Materials and Methods. Active members of the Society for Urologic Oncology were provided a 20-question survey. Descriptive statistical analysis was conducted for each question and univariate analysis was performed. Results. We achieved a response rate of 21%. Clinical T3/T4 disease was the most often selected reason for recommending NAC (87%). Concerns with recommending NAC were age and comorbidities (54%) followed by delay in surgery (35%). An association was identified between urologic oncologists who discussed NAC with >90% of their patients and medical oncologists "always" recommending NAC (P=0.0009). NAC utilization rate was between 30 and 57%. Conclusions. Amongst this highly specialized group of respondents, clinical T3-T4 disease was the most common reason for implementation of NAC. Respondents who frequently discussed NAC were more likely to report their medical oncologist always recommending NAC. Reported NAC use was higher in this surveyed group (30-57%) compared with recently published rates.

AB - Objectives. Level 1 evidence supports the use of neoadjuvant chemotherapy (NAC) to improve overall survival in muscle invasive bladder cancer; however utilization rates remain low. The aims of our study were to determine factors associated with NAC use, to more clearly define reasons for low utilization, and to determine the current rate of NAC use among urologic oncologists. Materials and Methods. Active members of the Society for Urologic Oncology were provided a 20-question survey. Descriptive statistical analysis was conducted for each question and univariate analysis was performed. Results. We achieved a response rate of 21%. Clinical T3/T4 disease was the most often selected reason for recommending NAC (87%). Concerns with recommending NAC were age and comorbidities (54%) followed by delay in surgery (35%). An association was identified between urologic oncologists who discussed NAC with >90% of their patients and medical oncologists "always" recommending NAC (P=0.0009). NAC utilization rate was between 30 and 57%. Conclusions. Amongst this highly specialized group of respondents, clinical T3-T4 disease was the most common reason for implementation of NAC. Respondents who frequently discussed NAC were more likely to report their medical oncologist always recommending NAC. Reported NAC use was higher in this surveyed group (30-57%) compared with recently published rates.

UR - http://www.scopus.com/inward/record.url?scp=84902142582&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902142582&partnerID=8YFLogxK

U2 - 10.1155/2014/746298

DO - 10.1155/2014/746298

M3 - Article

AN - SCOPUS:84902142582

JO - Advances in Urology

JF - Advances in Urology

SN - 1687-6369

M1 - 746298

ER -